berdazimer (Zelsuvmi)
Jump to navigation
Jump to search
Indications
- at home treatment of molluscum contagiosum (FDA-approved Jan 2024)[1]
* expected to be available in the U.S. by the 2nd half of 2024
Dosage
Adverse effects
- application site reactions[1]
Mechanism of action
- gel contains a nitric oxide-releasing agent with antiviral activity
- precise mechanism of action unknown[1]
* effects not spectacular
- 30% of patients with complete or near complete response
- 10-15% improvement over control group[1]
More general terms
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 1.4 1.5 Bankhead C At-Home Treatment for Molluscum Contagiosum Wins FDA Approval. Berdazimer gel led to 30% complete/near-complete clearance after 12 weeks in randomized trials. MedPage Today January 8, 2024 https://www.medpagetoday.com/dermatology/generaldermatology/108169